Insider filing
Traded Sep 2 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Aug 5, 2026 · Filed Aug 7, 2026
The CEO of Johnson & Johnson sold $1.69M of Johnson & Johnson shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$1,687,755
Shares × reported transaction price
21 days after results of Jul 15, 2026, 69 days before results of Oct 13, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $257.59 on Aug 5, 2026, within 4% of its 52-week high, after an 8% rise over the previous 30 trading days
52-week range $170.59 (Aug 6, 2025) to $267.24 (Jul 7, 2026), 90% of the way up, from 251 adjusted closes. 30 trading days earlier: $239.08 on Jun 23, 2026. Describes the past only, not a forecast
RSI 54, 13% above its 200-day average, 4% above its 50-day average, 4% below the 52-week high, 20-day volatility 24% a year, against the S&P 500: −7 points over 1 month, +8 points over 3 months, −1 points over 6 months
From the adjusted closes up to Aug 5, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Imaavy on Aug 24, 2026, 19 days after this trade.
New use approved (efficacy supplement). Active ingredient: Nipocalimab-Aahu. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +0.2% | −0.1% | +0.3% |
| 30 days | +2.0% | −1.4% | +3.4% |
| 90 days | +7.8% | −2.6% | +10.4% |
Past results only. Not a forecast.
Insider filing
Traded Sep 2 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Insider selling
Traded Sep 2 · filed 2 days laterNot reported under a pre-arranged trading plan
Johnson & Johnson's WW Chair, MedTech sold $3.04M of Johnson & Johnson shares. The filing does not indicate a pre-arranged trading plan.
Insider filing
Traded Sep 2 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.